Federal Register / Vol. 72, No. 65 / Thursday, April 5, 2007 / Notices 16799 

recommendations from the public. Once 

the PIN is finalized, it will be made 

available on HRSA’s Web site, along 

with the Agency’s ‘‘Response to Public 

Comments.’’ That document will 

summarize the major comments 

received and describe the Agency’s 

response, including any corresponding 

changes made to the PIN. Where 

comments do not result in a revision to 

the PIN, explanations will be provided. 

Background 

HRSA administers the Health Center 

Program, which supports more than 

3,800 health care delivery sites, 

including community health centers, 

migrant health centers, health care for 

the homeless centers, and public 

housing primary care centers. Health 

centers serve clients that are primarily 

low-income and minorities, and deliver 

preventive and primary care services to 

patients regardless of their ability to 

pay. Charges for health care services are 

set according to income. 

FTCA medical malpractice coverage 

for Health Center Program grantees was 

initially legislated through the Federally 

Supported Health Centers Assistance 

Act (FSHCAA) of 1992. The FSHCAA of 

1995 clarified the 1992 Act and 

eliminated its sunset provision, making 

the program permanent. FSCHAA 

authorizes Health Center Program 

grantees (and their officers, directors, 

employees, and certain contractors) to 

be deemed as Federal employees for the 

purpose of medical malpractice 

protection. As Federal employees, these 

organizations and individuals are 

immune from medical malpractice suits 

for actions within the scope of their 

project and employment. In the event 

that a medical malpractice lawsuit is 

filed against a deemed entity or covered 

physician acting within the scope of 

his/her employment in grant-related 

activities, the United States is 

substituted for the deemed entity and 

the covered employee. 

HRSA recognizes that, during an 

emergency, FTCA-deemed health 

centers are likely to participate in 

medical response efforts. HRSA has 

received numerous requests for 

clarification regarding the scope of 

FTCA coverage during emergencies. The 

purpose of the FTCA PIN is to respond 

to these requests for clarification and to 

address frequently asked FTCA 

questions. 

FOR FURTHER INFORMATION CONTACT: For 

questions regarding this notice, please 

contact Shannon Dunne Faltens at 301–

594–4060. 

Dated: March 29, 2007. 

Elizabeth M. Duke, 

Administrator. 

[FR Doc. E7–6366 Filed 4–4–07; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

Public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Molecular 

Oncology P01 Special Emphasis Panel. 

Date: June 4–5, 2007. 

Time: 8 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Bethesda North Hotel & 

Conference Center, 5701 Marinelli Road, 

North Bethesda, MD 20852. 

Contact Person: Michael B. Small, PhD, 

Scientific Review Administrator, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Blvd., Room 8127, Bethesda, MD 

20892–8328, 301–402–0996, 

smallm@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Cellular 

and Tissue Biology (SEP). 

Date: June 4–5, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Bethesda North Conference 

Center, 5701 Marinelli Road, Bethesda, MD 

20852. 

Contact Person: Shakeel Ahmad, PhD, 

Scientific Review Administrator, Research 

Projects Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8137, 

MSC 8328, Bethesda, MD 20892, (301) 594–

0114, ahmads@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Prevention, 

Control and Population Science. 

Date: June 7, 2007. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Bethesda North Hotel & 

Conference Center, 5701 Marinelli Road, 

North Bethesda, MD 20852. 

Contact Person: Wlodek Lopaczynski, MD, 

PhD, Scientific Review Administrator, 

Research Programs Review Branch, Division 

of Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd. Room 8131, 

Bethesda, MD 20892, 301–593–1402, 

lopacw@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: March 27, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1694 Filed 4–4–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

Public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Initial Review Group; Subcommittee 

A—Cancer Centers. 

Date: April 24, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Gail J. Bryant, MD., 

Scientific Review Administrator, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8107, 

MSC 8328, Bethesda, MD 20892–8328, (301) 

402–0801, gb30t@nih.gov. 


jlentini on PROD1PC65 with NOTICES